Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Perampanel 10 mg Tablets in Healthy Adults
NCT06450236Phase 1Completed
- Sponsor
- Humanis
- Start
- Nov 2023
- Primary completion
- Nov 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of perampanel in epilepsy (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 23 hours and Area under the curve from time 0 to 72 hours. Started Nov 2023; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06450236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450236.